Nanostructured Lipid Carrier-Based Hydrogel of Anisomeles malabarica for Enhanced Topical Management of Psoriasis

Psoriasis is a chronic immunity based inflammatory skin disorder characterized by
hyperproliferation of skin layer on keratinocytes and dysregulated immune responses,
leading to significant impairment in patient quality of life. Conventional topical therapies
are very limited by poor skin penetration, systemic toxicity, and reduced patient
compliance. In the present study, a nanostructured lipid carrier (NLC)-based hydrogel
incorporating Anisomeles malabarica leaf extract was developed to enhance topical
delivery and therapeutic efficacy against psoriasis. The ethanolic extract of Anisomeles
malabarica was prepared by cold maceration technique and it’s characterized by using
phytochemical screening, Fourier transform infrared spectroscopy (FTIR), and gas
chromatography–mass spectrometry (GC–MS), confirming the presence of bioactive
constituents including flavonoids, terpenoids, and phenolic compounds. NLCs were
formulated using hot homogenization followed by ultrasonication and subsequently
incorporated into a Carbopol-based hydrogel. The developed formulation was
evaluating such as particle size, zeta potential, viscosity, spreadability, drug content,
and stability. In vitro release studies demonstrated sustained and controlled release
behaviour, indicating better activity on topical delivery and prolonged therapeutic effect.
Furthermore, molecular docking analysis reflects the strong binding affinity,of
anisomelic acid toward cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5
LOX),,suggesting the dual activity of anti-inflammatory and potential therapeutic activity
that,relevance in psoriasis management. The optimized process of NLC-based
hydrogel exhibited improve in the physicochemical stability, enhanced the permeation
characteristics, and targeted drug delivery potency. These findings suggest that
Anisomeles malabarica-loaded NLC hydrogel represents a promising, effective, and
safer alternative for already existed topical psoriasis therapy, warranting further
preclinical and clinical investigations best future Implemented Drug System for
therapeutic activity,K